^
    Back
    Association details:
    Biomarker:TERC overexpression
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:sunitinib (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Biol Sex Differ
    Title:

    Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma

    Published date:
    07/12/2023
    Excerpt:
    DKC1 and TERC expression correlated positively with each other, and higher TERC expression predicted poor Sunitinib response (P = 0.031) and shorter PFS (P = 0.004), too.
    DOI:
    10.1186/s13293-023-00526-7